Phreesia, Inc. Stock Research

Market Summary

USD32.29+1.44

Market Closed

4.67%

PHR Stock Price

PHR RSI Chart

PHR Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-9.2

Price/Sales (Trailing)

6.47

EV/EBITDA

-9.08

Price/Free Cashflow

-14.39

PHR Price/Sales (Trailing)

PHR Profitability

EBT Margin

-70.27%

Return on Equity

-57.62%

Return on Assets

-46.46%

Free Cashflow Yield

-6.95%

PHR Fundamentals

PHR Revenue

Revenue (TTM)

262.3M

Revenue Y/Y

30.74%

Revenue Q/Q

7.72%

PHR Earnings

Earnings (TTM)

-184.6M

Earnings Y/Y

-10.52%

Earnings Q/Q

14.02%

Price Action

52 Week Range

13.1940.00

(Low)(High)

Last 7 days

2.5%

Last 30 days

-12.0%

Last 90 days

-0.2%

Trailing 12 Months

22.5%

PHR Financial Health

Current Ratio

3.94

Debt/Equity

0.01

Debt/Cashflow

-29.79

PHR Investor Care

Shares Dilution (1Y)

3.11%

Diluted EPS (TTM)

-3.57

Peers (Alternatives to Phreesia)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	441.4B	324.2B	-0.20%	-6.09%	21.94	1.36	12.71%	16.40%
VEEV	28.6B	2.1B	10.63%	-13.49%	72.07	13.75	17.88%	-8.53%
CERN	27.9B	-	0.98%	20.75%	47.36	4.81	-	-
MID-CAP
CHNG	9.0B	3.5B	11.88%	31.28%	-116.8	2.57	7.15%	-34.72%
TDOC	4.2B	2.4B	0.08%	-64.09%	-0.31	1.75	18.41%	-3085.58%
OMCL	2.6B	1.3B	2.68%	-54.69%	464.82	2.03	14.48%	-92.74%
SMALL-CAP
PHR	1.7B	262.3M	-11.99%	22.50%	-9.2	6.47	33.16%	-131.28%
MDRX	1.4B	837.2M	-9.94%	-42.05%	23.52	1.7	3.88%	-92.18%
NXGN	1.1B	625.9M	-3.12%	-16.74%	50.13	1.84	6.21%	3223.77%
SLP	892.6M	53.5M	14.82%	-13.81%	83.4	16.7	10.94%	3.61%
HSTM	828.7M	266.8M	6.53%	36.04%	68.54	3.11	3.94%	106.86%
CCRN	810.3M	2.8B	-16.25%	3.00%	4.3	0.29	67.39%	42.77%
HCAT	644.9M	276.2M	-18.51%	-55.34%	-4.69	2.33	14.18%	10.32%
OPRX	267.2M	63.1M	-19.22%	-61.20%	-25.47	4.23	9.93%	-1043.45%
TRHC	151.4M	357.1M	-7.60%	-2.95%	-1.09	0.42	33.22%	-57.66%

Financials for Phreesia

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	7.0%	262,344,000	245,156,000	228,296,000	213,233,000	197,021,000
S&GA Expenses	3.1%	152,209,000	147,614,000	131,440,000	106,421,000	82,174,000
R&D Expenses	9.7%	83,341,000	75,945,000	64,846,000	52,265,000	41,125,000
EBITDA	-1.4%	-164,403,000	-162,125,000	-140,247,000	-	-
EBITDA Margin	5.2%	-0.63	-0.66	-0.61	-	-
Earnings Before Taxes	-2.1%	-184,355,000	-180,559,000	-158,161,000	-117,979,000	-79,513,000
EBT Margin	4.6%	-0.70	-0.74	-0.69	-	-
Interest Expenses	30.3%	-856,000	-1,228,000	-1,229,000	-1,084,000	-1,123,000
Net Income	-2.1%	-184,576,000	-180,752,000	-158,429,000	-118,161,000	-79,806,000
Net Income Margin	4.6%	-0.70	-0.74	-0.69	-	-
Free Cahsflow	10.6%	-118,055,000	-132,008,000	-119,092,000	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-6.7%	397	426	459	494	529
Current Assets	-9.4%	287	316	349	386	464
Cash Equivalents	-12.9%	210	241	269	314	400
Goodwill	0%	34.00	34.00	34.00	34.00	8.00
Liabilities	-0.7%	77.00	78.00	78.00	77.00	71.00
Current Liabilities	1.1%	73.00	72.00	71.00	68.00	65.00
Long Term Debt	-23.7%	4.00	5.00	6.00	7.00	5.00
Shareholder's Equity	-8.1%	320	348	381	417	458
Retained Earnings	-7.6%	-568	-527	-481	-429	-383
Additional Paid-In Capital	1.7%	912	896	881	861	849
Shares Outstanding	0.5%	53.00	52.00	52.00	51.00	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	3.3%	-112	-115	-102	-74.71	-32.65
Share Based Compensation	3.6%	54.00	52.00	45.00	36.00	30.00
Cashflow From Investing	11.4%	-60.27	-68.05	-65.35	-65.23	-38.54
Cashflow From Financing	-21.5%	-18.33	-15.09	-13.27	235	217

Risks for PHR

What is the probability of a big loss on PHR?

82.0%

Probability that Phreesia stock will be more than 20% underwater in next one year

81.0%

Probability that Phreesia stock will be more than 30% underwater in next one year.

76.4%

Probability that Phreesia stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PHR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Phreesia was unfortunately bought at previous high price.

Drawdowns

Returns for PHR

Cumulative Returns on PHR

15.4%

3-Year Cumulative Returns

Which funds bought or sold PHR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	unchanged	-	183,778	864,400	0.01%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-1.37	29,000	144,000	-%
2023-02-28	Voya Investment Management LLC	reduced	-85.16	-2,921,480	678,524	-%
2023-02-24	SRS Capital Advisors, Inc.	unchanged	-	391	1,391	-%
2023-02-21	MACQUARIE GROUP LTD	reduced	-32.61	-350,000	1,918,000	-%
2023-02-15	Jasper Ridge Partners, L.P.	unchanged	-	143,803	674,803	0.04%
2023-02-15	LAZARD ASSET MANAGEMENT LLC	reduced	-43.43	-3,437,000	8,771,000	0.01%
2023-02-15	JANE STREET GROUP, LLC	reduced	-6.43	55,951	352,951	-%
2023-02-15	Capital Impact Advisors, LLC	added	4.17	200,038	688,038	0.67%
2023-02-15	PFS INVESTMENTS INC.	new	-	212,000	212,000	-%

Latest Funds Activity

Are funds buying PHR calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own PHR

No. of Funds

Phreesia News

Schedule 13G FIlings of Phreesia

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	t. rowe price investment management, inc.	5.1%	2,676,879	SC 13G
Feb 14, 2023	price t rowe associates inc /md/	0.3%	180,384	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	brown advisory inc	5.8%	3,068,782	SC 13G
Feb 09, 2023	vanguard group inc	7.34%	3,872,425	SC 13G/A
Jan 25, 2023	blackrock inc.	8.7%	4,564,585	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	15.2%	7,797,879	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 07, 2022	blackrock inc.	11.7%	6,010,340	SC 13G/A
May 10, 2021	price t rowe associates inc /md/	10.7%	5,402,206	SC 13G/A

PHR Fair Value

Phreesia fair value in different scenarios

The table shows the Fair Value estimates for Phreesia for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	2.46 -92.38%	3.60 -88.85%	7.20 -77.70%	11.86 -63.27%	16.25 -49.67%
Current Inflation	2.38 -92.63%	3.39 -89.50%	6.50 -79.87%	10.46 -67.61%	14.19 -56.05%
Very High Inflation	2.27 -92.97%	3.12 -90.34%	5.66 -82.47%	8.84 -72.62%	11.81 -63.43%

Historical Phreesia Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Phreesia

View All Filings

Date Filed	Form Type	Document
Mar 28, 2023	3	Insider Trading
Mar 28, 2023	3	Insider Trading
Mar 28, 2023	4	Insider Trading
Mar 23, 2023	10-K	Annual Report
Mar 23, 2023	4/A	Insider Trading
Mar 23, 2023	S-8	Employee Benefits Plan
Mar 22, 2023	8-K	Current Report
Mar 22, 2023	8-K	Current Report
Mar 20, 2023	4	Insider Trading
Feb 14, 2023	SC 13G	Major Ownership Report

Latest Insider Trading transactions for PHR

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-24	Gandhi Balaji	acquired	-	-	21,428	chief financial officer
2023-03-17	Linetsky David	sold (taxes)	-605	33.65	-18.00	svp, life sciences
2023-03-16	Linetsky David	sold (taxes)	-6,683	34.81	-192	svp, life sciences
2023-03-15	Linetsky David	sold (taxes)	-879	33.84	-26.00	svp, life sciences
2023-02-02	Rasmussen Randy	sold	-190,600	40.00	-4,765	chief financial officer
2023-02-02	VanDuyn Amy Beth	sold	-12,000	40.00	-300	svp, human resources
2023-02-02	Linetsky David	sold	-449,989	39.549	-11,378	svp, life sciences
2023-02-02	Davidoff Michael J.	sold	-294,564	39.2073	-7,513	svp, payer business
2023-01-31	Davidoff Michael J.	sold	-124,082	38.0037	-3,265	svp, payer business
2023-01-31	Munson Gillian	acquired	9,972	37.49	266	-

About Phreesia

Chaim Indig

www.phreesia.com

1700

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.

PHR Income Statement

2023-01-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Revenue:
Total revenue	$ 280,910	$ 213,233	$ 148,677
Expenses:
Cost of revenue (excluding depreciation and amortization)	58,944	42,669	23,461
Payment processing expense	50,323	38,719	28,925
Sales and marketing	151,263	106,421	42,972
Research and development	91,244	52,265	22,622
General and administrative	80,384	68,674	40,460
Depreciation	17,988	14,985	9,770
Amortization	7,316	6,317	6,138
Total expenses	457,462	330,050	174,348
Operating loss	(176,552)	(116,817)	(25,671)
Other (expense) income, net	(175)	(78)	1
Interest income (expense), net	1,064	(1,084)	(1,573)
Total other income (expense), net	889	(1,162)	(1,572)
Loss before provision for income taxes	(175,663)	(117,979)	(27,243)
Provision for income taxes	(483)	(182)	(49)
Net loss	$ (176,146)	$ (118,161)	$ (27,292)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (3.36)	$ (2.37)	$ (0.69)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (3.36)	$ (2.37)	$ (0.69)
Weighted-average common shares outstanding - basic (in shares)	52,440,067	49,888,436	39,519,640
Weighted-average common shares outstanding - diluted (in shares)	52,440,067	49,888,436	39,519,640
Subscription and related services
Revenue:
Total revenue	$ 128,975	$ 95,514	$ 69,042
Payment processing fees
Revenue:
Total revenue	78,368	65,201	49,900
Network solutions
Revenue:
Total revenue	$ 73,567	$ 52,518	$ 29,735

PHR Balance Sheet

2023-01-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Current:
Cash and cash equivalents	$ 176,683	$ 313,812
Settlement assets	22,599	19,590
Accounts receivable, net of allowance for doubtful accounts of $1,053 and $863 as of January 31, 2023 and 2022, respectively	51,394	40,262
Deferred contract acquisition costs	1,056	1,642
Prepaid expenses and other current assets	10,709	11,043
Total current assets	262,441	386,349
Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively	21,670	34,645
Capitalized internal-use software, net of accumulated amortization of $37,236 and $31,139 as of January 31, 2023 and 2022, respectively	35,150	17,643
Operating lease right-of-use assets	569	2,337
Deferred contract acquisition costs	1,754	2,437
Intangible assets, net of accumulated amortization of $2,549 and $1,178 as of January 31, 2023 and 2022, respectively	11,401	12,772
Deferred tax asset	81	515
Goodwill	33,736	33,621
Other assets	3,255	4,157
Total Assets	370,057	494,476
Current:
Settlement obligations	22,599	19,590
Current portion of finance lease liabilities and other debt	5,172	5,821
Current portion of operating lease liabilities	934	1,281
Accounts payable	10,836	5,119
Accrued expenses	21,810	20,128
Deferred revenue	17,688	16,493
Total current liabilities	79,039	68,432
Long-term finance lease liabilities and other debt	2,725	7,423
Operating lease liabilities, non-current	349	1,276
Long-term deferred revenue	125	65
Total Liabilities	82,238	77,196
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2023 and 2022; 54,187,172 and 52,095,964 shares issued as of January 31, 2023 and 2022, respectively	542	521
Additional paid-in capital	926,957	860,657
Accumulated deficit	(606,084)	(429,938)
Treasury stock, at cost, 971,236 and 301,003 shares as of January 31, 2023 and 2022, respectively	(33,596)	(13,960)
Total Stockholders’ Equity	287,819	417,280
Total Liabilities and Stockholders’ Equity	$ 370,057	$ 494,476